Cargando…
Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells
Most breast cancer patients treated with anti-oestrogens will eventually develop resistance towards treatment. Therefore it is important to find new therapeutic agents effective for treatment of patients relapsing on anti-oestrogen. The vitamin D analogue EB1089 (Seocalcitol(TM)) is a promising new...
Autores principales: | Larsen, S S, Heiberg, I, Lykkesfeldt, A E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363804/ https://www.ncbi.nlm.nih.gov/pubmed/11237391 http://dx.doi.org/10.1054/bjoc.2000.1646 |
Ejemplares similares
-
A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer
por: Evans, T R J, et al.
Publicado: (2002) -
A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer.
por: Gulliford, T., et al.
Publicado: (1998) -
The vitamin D receptor agonist EB1089 can exert its antiviral activity independently of the vitamin D receptor
por: Jaratsittisin, Janejira, et al.
Publicado: (2023) -
EB1089 promotes the expression of vitamin D receptor in the intestinal epithelial cell line HT-29 and reduces lipopolysaccharide-induced inflammatory response
por: Lu, Dong, et al.
Publicado: (2022) -
SAT-353 The Synthetic Vitamin D Analog EB1089 Restricts Adrenocortical Tumor Proliferation in NCI-H295 Xenograft Model
por: Bueno, Ana, et al.
Publicado: (2019)